Sipuleucel-T (Provenge) is FDA approved after a man becomes castrate resistant. In clinical trials it has shown that it extends life when compared to placebo. The use of Provenge has raised many questions, the two most common ones are why PSA and disease progression continues while receiving this treatment (see post at for an explanation) [...]
There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical trials.gov site is NOT currently accurate. Additionally, there are [...]
We won't let you fight your prostate cancer alone. Our mission is simple. We are men, fighting cancer, together. We share lifesaving information about the newest treatments, best (and worst) doctors and clinical trial admissions. Our Advanced Prostate Cancer program, run by Joel, has helped several thousand men live longer and happier lives in the [...]
Researchers at the Harvard Medical School investigated the effect of androgen deprivation in a preclinical mouse model of stable high grade prostatic intraepithelial neoplasia induced by the loss of the PTEN tumor suppressor. They found that androgen deprivation treatment of these mice accelerated the progression to invasive disease. Shidong Jia, M.D., Ph.D. And associates found [...]
A comprehensive study of prostate cancer tissue done in the UK has revealed that a completely new gene network takes over driving the cancer in men who are castrate resistant. The research was published in Cancer Cell. Researchers at the Cancer Research UK Cambridge Research Institute, at the University of Cambridge studied tissue samples from [...]